Publications

  1. Paulose R, Chhablani J, Dedhia CJ, Stewart MW, Mansour AM. Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion Clin Ophthalmol 2016;10:1853-1858..2016;().
  2. Chhablani J, Stewart M, Paulose R, Gallego-Pinazo R, Dolz-Marco R. Clinical Characteristics and Treatment Outcomes of Recurrent Central Retinal Vein Occlusions. Semin Ophthalmol 2016 Sep 9; 1-7 Epub 2016 Sept 09
    View PubMed
  3. Stewart MW, Flynn HW Jr, Schwartz SG, Scott IU. Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects. Expert Opin Drug Deliv 2016 Sep; 13 (9):1277-87 Epub 2016 June 22
    View PubMed
  4. Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes 2016 Aug 25; 7 (16):333-41
    View PubMed
  5. Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges World J Diabetes 2016; 7(16): 333-341.
  6. Syed , Z, Stewart MW. Age-dependent vitreous separation from the macula in a clinic population. Clin Ophthalmol .2016; 10:1237-1243 Epub 2016 Jul 7;
  7. Gutierrez-Aguirre KI, Stewart MW, Sluzevich JC. SCLEROMYXEDEMA WITH RETINAL VASCULITIS AND MACULAR EDEMA. Retin Cases Brief Rep 2016 Jun 24 Epub 2016 June 24
    View PubMed
  8. Stewart MW, Narayanan R, Gupta V, Rosenfeld PJ, Martin DF, Chakravarthy U. Counterfeit Avastin in India: Punish the Criminals, Not the Patients. Am J Ophthalmol 2016 Jun 7 Epub 2016 June 07
    View PubMed
  9. Narayanan R, Stewart MW, Panchal B, Das T, Chhablani J, Jalali S, Hasnat Ali M. Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2 Clinical Ophthalmology.;2016(10)1023-1029.
  10. Chhablani J, Narayanan R, Mathai A, Yogi R, Stewart M. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT. Retina 2016 Jun; 36 (6):1126-31
    View PubMed
  11. Browning DJ, Lee C, Stewart MW, Landers MB III. Vitrectomy for center-involved diabetic macular edema Clinical Ophthalmology.;2016(10)735-742.
  12. Yogi R, Stewart M, Chhablani J. FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT. Retin Cases Brief Rep 2016 Apr 13 [Epub ahead of print]
    View PubMed
  13. Stewart MW, Landers MB 3rd, Browning DJ, Murata T, Ohji M, Nawrocki J, Chhablani JK. Correspondence. Retina 2016 Mar; 36 (3):e22-3
    View PubMed
  14. Browning DJ, Lee C, Stewart MW, Landers MB 3rd. Vitrectomy for center-involved diabetic macular edema. Clin Ophthalmol 2016; 10:735-42 Epub 2016 Apr 26
    View PubMed
  15. Narayanan R, Panchal B, Stewart MW, Das T, Chhablani J, Jalali S, Hasnat Ali M. Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2. Clin Ophthalmol 2016; 10:1023-9 Epub 2016 June 02
    View PubMed
  16. Schwartz SG, Scott IU, Stewart MW, Flynn HW Jr. Update on corticosteroids for diabetic macular edema. Clin Ophthalmol 2016; 10:1723-30 Epub 2016 Sept 08
    View PubMed
  17. Narayanan R, Panchal B, Stewart MW, Das T, Chhablani J, Jalali S, Ali MH. Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2 Clinical Ophthalmology 2016; 10:1023-9
  18. Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY. CONTINUED BEVACIZUMAB MONOTHERAPY. Retina 2015 Aug; 35 (8):1604-14
    View PubMed
  19. Schwartz SG, Scott IU, Stewart MW, Flynn HW Jr. . Update on corticosteroids for diabetic macular edema. Clin Ophthalmol 2016;10:1723-1730.2015;().
  20. Stewart MW. Anti-Vascular Endothelial Growth Factor Therapy for Chorioretinal Vascular Diseases: An Update. Current Medical Literature Ophthalmology.2015;25:(3):61-71.
  21. Stewart MW. Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing? J Clin Med. 2015; 4(5):1079-101. Epub 2015 May 21.
    View PubMed
  22. Stewart MW, Pulido J, Nicholson B, Freund KB. Unusual vascular lesion unresponsive to bevacizumab. Intravitreal Interventions. 2015; 4(1).
  23. Stewart MW. The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes. 2015; 8:473-482.
  24. Stewart MW. Case Presentation: diabetic macular edema unresponsive to bevacizumab. Intravitreal Interventions. 2015; 4(2).
  25. Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep. 2014 Aug; 14(8):510.
    View PubMed
  26. Moore SA, Rabinstein AA, Stewart MW, David Freeman W. Recognizing the signs and symptoms of aneurysmal subarachnoid hemorrhage. Expert Rev Neurother. 2014 Jul; 14(7):757-68.
    View PubMed
  27. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014 Mar; 7(2):167-80. Epub 2014 Feb 03.
    View PubMed
  28. Schwartz SG, Scott IU, Flynn HW Jr, Stewart MW. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv. 2014 Jan; 11(1):61-8. Epub 2013 Nov 13
    View PubMed
  29. Maturi RK, Chen V, Raghinaru D, Bleau L, Stewart MW. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clin Ophthalmol. 2014; 8:1057-64. Epub 2014 Jun 03.
    View PubMed
  30. Kaiser PK, Brown DM, Kitchens JW, MacCumber MW, Singh RP, Stewart MW. The impact of anti-VEGF treatments on naïve AMD patients. How to choose an agent Part 1 Retinal Physician. 2014; June Suppl:1-17.
  31. Stewart MW. Clinically relevant pharmacology of anti-VEGF agents. Intravitreal Interventions. 2014; 3(1):1, 4-6.
  32. Stewart MW. Review of the latest treatments for retinal vein occlusions: Emphasis on pharmacologic therapy. Expert Rev. Ophthalmol. 2014; 9(5):361-74.
  33. Vanner EA, Stewart MW. Meta-analysis comparing same-day versus delayed vitrectomy clinical outcomes for intravitreal retained lens fragments after age-related cataract surgery. Clin Ophthalmol. 2014; 8:2261-76. Epub 2014 Nov 18.
    View PubMed
  34. Stewart MW. Sudden vision loss with optic disc swelling and retinal hemorrhages. Intravitreal Interventions 20. 2014; 3(3):17.
  35. Smith CD, Spackman T, Brommer K, Stewart MW, Vizzini M, Frye J, Rupp WC. Re-engineering the operating room using variability methodology to improve health care value. J Am Coll Surg. 2013 Apr; 216(4):559-68; discussion 568-70.
    View PubMed
  36. Stewart MW. Herpetic (non-cytomegalovirus) retinal infections in patients with the acquired immunodeficiency syndrome. Curr HIV Res. 2013 Apr; 11(3):210-9.
    View PubMed
  37. Stewart MW. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Mar; 6(2):103-13.
    View PubMed
  38. Stewart MW, Stewart ML. Topical azithromycin or ofloxacin for endophthalmitis. Clin Ophthalmol. 2013; 7:35-6. Epub 2012 Dec 31
    View PubMed
  39. Stewart MW. Review of aflibercept for the treatment of neovascular age-related macular degeneration. Clinical Medicine Insights: Therapeutics. 2013; 5:81-93.
  40. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Ocular Times. 2013.
  41. Stewart MW. Aflibercept as a treatment for age-related macular degeneration. US Ophthalmic Reviews. 2013; 6(1):58-63.
  42. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol. 2013; 7:1257-67. Epub 2013 Jun 24.
    View PubMed
  43. Stewart MW. 1-year results of intravitreal aflibercept treatment for macular edema due to central retinal vein occlusion. Expert Rev. Ophthalmol. 2013; 8(3):241-4.
  44. Stewart MW. Aflibercept in the treatment of wet macular degeneration. J Signs Symptoms. 2013; 2(4):203-212.
  45. Stewart MW. One-year results of intravitreal ranibizumab 0.5 mg vs 20 mg for the treatment of exudative age-related macular degeneration. Expert Rev Ophthalmol. 2013; 8(4):341-345.
  46. Stewart MW. Aflibercept Ophthalmic Solution: Drug development and clinical uses. Clinical Investigation. 2013; 3(11):1045-56.
  47. Stewart MW. PDGF: ophthalmology's next great target. Exp Rev Ophthalmol. 2013; 8(6):527-537.
  48. Forlenza GP, Stewart MW. Diabetic retinopathy in children. Pediatr Endocrinol Rev. 2012 Dec-2013 Jan; 10(2):217-26.
    View PubMed
  49. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012 Aug; 12(4):364-75.
    View PubMed
  50. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug; 154(2):222-6.
    View PubMed
  51. Stewart MW. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev. 2012 Jul 1; 8(4):237-46.
    View PubMed
  52. Butendieck RR, Parikh K, Stewart M, Davidge-Pitts C, Abril A. Systemic lupus erythematosus-associated retinal vasculitis. J Rheumatol. 2012 May; 39(5):1095-6.
    View PubMed
  53. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012 Mar; 32(3):434-57.
    View PubMed
  54. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol. 2012 Feb; 153(2):196-203.e1.
    View PubMed
  55. Stewart MW. Human immunodeficiency virus and its effects on the visual system. Infect Dis Rep. 2012 Jan 2; 4(1):e25. Epub 2012 Mar 08.
    View PubMed
  56. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012 Jan; 87(1):77-88.
    View PubMed
  57. Stewart MW. Vascular endothelial growth factor (VEGF) biochemistry and development of inhibitory drugs. Current Drug Therapy. 2012; 7(2):80-9.
  58. Stewart MW. Vascular endothelial growth factor inhibitor use in ophthalmology: The revolution continues. Current Drug Therapy. 2012; 7(2):77-9.
  59. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012; 6:1175-86. Epub 2012 Jul 26.
    View PubMed
  60. Stewart MW. Pharmacokinetics of intravitreal anti-VEGF agents: practical clinical implications. Intervitreal Interventions. 2012; 1(1):1-4.
  61. Vanner EA, Stewart MW, Liesegang TJ, Bendel RE, Bolling JP, Hasan SA. A retrospective cohort study of clinical outcomes for intravitreal crystalline retained lens fragments after age-related cataract surgery: a comparison of same-day versus delayed vitrectomy. Clin Ophthalmol. 2012; 6:1135-48. Epub 2012 Jul 18.
    View PubMed
  62. Stewart MW. Unilateral vision loss following contralateral eye treatment. Intravitreal Interventions. 2012; 1(2):13.
  63. Stewart MW. New anti-VEGF antibody therapies in Ophthalmology. Curr Med Literature - Ophthalmology. 2012; 22(4):105-113.
  64. Stewart MW. Early experience using aflibercept in the treatment of wet macular degeneration. Intravitreal Interventions. 2012; 1(4):1-11.
  65. Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets. 2011 Dec; 10(6):497-508.
    View PubMed
  66. Davis J, Olsen TW, Stewart M, Sternberg P Jr. How the comparison of age-related macular degeneration treatments trial results will impact clinical care. Am J Ophthalmol. 2011 Oct; 152(4):509-14.
    View PubMed
  67. Vanner EA, Stewart MW. Vitrectomy timing for retained lens fragments after surgery for age-related cataracts: a systematic review and meta-analysis. Am J Ophthalmol. 2011 Sep; 152(3):345-357.e3. Epub 2011 Jun 17.
    View PubMed
  68. Stewart MW. Impact of HIV on vision. Northeast Florida Medicine. 2011; 62(2):3-8.
  69. Stewart MW, Vavra MW, Whaley NR. Fundus findings in a patient with [alpha]-methylacyl-CoA racemase deficiency. Retinal Cases and Brief Reports. 2011; 5(3):262-266.
  70. Stewart MW. What are the half-lives of ranibizumab, aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Reports. 2011; 1(1):12-14.
  71. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol. 2010; 4:285-99. Epub 2010 Apr 26.
    View PubMed
  72. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May; 92(5):667-8. Epub 2008 Mar 20.
    View PubMed
  73. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina. 2007 Nov-Dec; 27(9):1196-200.
    View PubMed
  74. Shetty RK, Boilling JP, Stewart MW, Heckman MG. Differences in optical coherence tomography of the macula in advanced glaucoma and after a retinal artery occlusion. Ophthalmic Surg Lasers Imaging. 2007 Sep-Oct; 38(5):392-8.
    View PubMed
  75. Stewart MW, Brazis PW, Guier CP, Thota SH, Wilson SD. Purtscher-like retinopathy in a patient with HELLP syndrome. Am J Ophthalmol. 2007 May; 143(5):886-7.
    View PubMed
  76. Hasan SA, Stewart MW. Cystoid macular edema following photorefractive keratectomy complicated by presumptive infectious keratitis. J Cataract Refract Surg. 2007 Feb; 33(2):348-9.
    View PubMed
  77. Stewart MW. Intravitreal bevacizumab (avastin) for the treatment of chorioretinal vascular diseases. Techniques in Ophthalmology. 2007; 5(1):40-5.
    View PubMed
  78. Stewart MW, Alvarez S, Ginsburg WW, Shetty R, McLain WC, Sleater JP. Visual recovery following Mycobacterium chelonae endophthalmitis. Ocul Immunol Inflamm. 2006 Jun; 14(3):181-3.
    View PubMed
  79. Hellinger WC, Hasan SA, Bacalis LP, Thornblom DM, Beckmann SC, Blackmore C, Forster TS, Tirey JF, Ross MJ, Nilson CD, Mamalis N, Crook JE, Bendel RE, Shetty R, Stewart MW, Bolling JP, Edelhauser HF. Outbreak of toxic anterior segment syndrome following cataract surgery associated with impurities in autoclave steam moisture. Infect Control Hosp Epidemiol. 2006 Mar; 27(3):294-8. Epub 2006 Feb 22.
    View PubMed
  80. Stewart MW, Landers MB. Transscleral intraocular lens fixation with a "homemade" needle and hook. J Cataract Refract Surg. 2006 Feb; 32(2):200-2.
    View PubMed
  81. Stewart MW, Liesegang TJ, Schwam BL. Chlamydia conjunctivitis and central retinal vein occlusion. Am J Ophthalmol. 2005 Jul; 140(1):161-2.
    View PubMed
  82. Stewart MW, Brazis PW, Barrett KM, Eidelman BH, Mendez JC. Optical coherence tomography in a case of bilateral neuroretinitis. J Neuroophthalmol. 2005 Jun; 25(2):131-3.
    View PubMed
  83. Stewart MW. Intraoperative radiographic detection of a "lost" scleral plug. Retina. 2005 Jun; 25(4):526-7.
    View PubMed
  84. Stewart MW, Bolling JP, Mendez JC. Cytomegalovirus retinitis in an immunocompetent patient. Arch Ophthalmol. 2005 Apr; 123(4):572-4.
    View PubMed
  85. Stewart MW. Treatment of an avulsed retinal vessel with infrared diode laser photocoagulation. Am J Ophthalmol. 2004 Apr; 137(4):767-8.
    View PubMed
  86. Brazis PW, Stewart M, Lee AG. The uveo-meningeal syndromes. Neurologist. 2004; 10(4):171-84.
    View PubMed
  87. Brazis PW, Lee AG, Stewart M, Capobianco D. Clinical review: The differential diagnosis of pain in the quiet eye. Neurologist. 2002; 8(2):82-100.
    View PubMed
  88. Stewart MW. Choroidal melanoma. Jacksonville Medicine. 2000; 51:393-399.
  89. Stewart MW, Lambrou FH Jr. AIDS Retinopathy. Jacksonville Medicine. 1997; 48:347-51.
  90. Stewart MW, Lambrou FH Jr, Watson M. Intravitreal ganciclovir injections for the treatment of cytomegalovirus retinitis. Ophthalmology. 1997; 104(Suppl):S149.
    View PubMed
  91. Skowsky WR, Siddiqui T, Hodgetts D, Lambrou FH, Stewart MW, Foster MT Jr. A pilot study of chronic recombinant interferon-alfa 2a for diabetic proliferative retinopathy: metabolic effects and ophthalmologic effects. J Diabetes Complications. 1996; 10(2):94-9.
    View PubMed
  92. Stewart MW. Update on CMV retinitis. Review of Ophthalmol. 1994 Nov:5-52.
  93. Pogrebniak AE, Bolling JP, Stewart MW. Argon laser-induced cataract in an infant with retinopathy of prematurity. Am J Ophthalmol. 1994 Feb 15; 117(2):261-2.
    View PubMed
  94. Friedman SM, Mames RN, Stewart MW. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafovealar retinal telangiectasis. Ophthalmol Surg. 1993; 24:551-3.
  95. Lambrou FH, Stewart MW. Management of dislocated lens fragments during phacoemulsification. Ophthalmology. 1992 Aug; 99(8):1260-2; discussion 1268-9.
    View PubMed
  96. Hjelmeland LM, Stewart MW, Li J, Toth CA, Burns MS, Landers MB III. An experimental model of ectropion uveae and iris neovascularization in the cat. Invest Ophthalmol Vis Sci. 1992; 33(5):1796-803.
    View PubMed
  97. Stewart MW, Lambrou FH Jr. Management of dislocated lens fragments: Pars plana vitrectomy and transscleral fixation of posterior chamber lens implants. Vitreoretinal Surg and Tech. 1992; 4(3):5-6.
  98. Landers MBL III, Stewart MW, Maberely D, Serdahl C. A new inexpensive pump for vitreoretinal surgery. Arch Ophthalmol. 1991; 109:142-3.
    View PubMed
  99. Arora N, Lambrou FH Jr, Stewart MW, et al. Sudden blindness associated with central nervous symptoms in a hemodialysis patient. Nephron. 1991; 59:490-2.
    View PubMed
  100. Lambrou FH, Stewart MW. Management of dislocated lens fragments. Ophthalmol. 1991; 98(Suppl 8):169.
  101. Sternberg P Jr, Meredith TA, Stewart MW, Kaplan HJ. Retinal detachment in penetrating keratoplasty patients. Am J Ophthalmol. 1990; 109:148-52.
    View PubMed
  102. Stewart MW, Lambrou FH Jr. Lasers and retina surgery. Jacksonville Medicine. 1990; 41:448-50.
  103. Stewart MW, Gitter KA, Cohen G. Acute leukemia presenting as a unilateral exudative retinal detachment. Retina. 1989; 9:110-4.
    View PubMed
  104. Gitter KA, Stewart MW, She SC, Paulus P, Cohen G. Practical management of diabetic retinopathy. J La State Med Soc. 1988 Oct; 140(10):26-38.
    View PubMed
  105. Stewart MW, Gitter KA. Inherited retinal venous beading. Am J Ophthalmol. 1988; 106:675-81.
    View PubMed